Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00174824 · ClinicalTrials.gov registry record · Phase 4
Comparison of Insulin Glargine and NPH Human Insulin in Progression of Diabetic Retinopathy in Type 2 Diabetic Patients
A Phase 4 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,024
- Enrollment target
NCT00174824: Completed Phase 4 study, sponsored by Sanofi.
NCT00174824 is a Phase 4 study that has completed, run by Sanofi. The registered enrollment target is 1,024 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00174824, a Phase 4 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,024 participants
- Enrollment target
Study Summary
To compare the progression of diabetic retinopathy in type 2 diabetic patients with mild-to-moderate diabetic retinopathy treated with insulin glargine vs NPH human insulin.
Interventions
- DRUG Insulin glargine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,024 participants |
| Start Date | 2001-06 |
| Est. Completion | 2007-04 |
| Phase | Phase 4 |
What the finished NCT00174824 record still lists
NCT00174824 is an interventional study that assigns participants to a tested intervention. Its 1,024 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% higher).
The record links to 0 conditions, and to 1 intervention - of which Insulin glargine is the first listed.
NCT00174824 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00174824 about?
NCT00174824 is a clinical study titled "Comparison of Insulin Glargine and NPH Human Insulin in Progression of Diabetic Retinopathy in Type 2 Diabetic Patients". To compare the progression of diabetic retinopathy in type 2 diabetic patients with mild-to-moderate diabetic retinopathy treated with insulin glargine vs NPH human insulin.
What is the current status of trial NCT00174824?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,024 participants. The study started on 2001-06. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00174824?
The interventions under investigation include: Insulin glargine (DRUG).
Who is sponsoring clinical trial NCT00174824?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00174824's enrollment target sits among peer trials
1,024 66th of 2000 higher than 1,935 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06888011 · 1,024 participants · NA
iAmHealthy Clinical Practice Guideline (CPG)
- NCT02200276 · 1,025 participants · NA
Influenza Immunization in Adults Over Age 75
- NCT02296450 · 1,025 participants
Quality of Life (QoL) Assessment in Cancer Patients and Survivors With Dermatologic Conditions Using Dermatologic QoL Instruments
- NCT07216703 · 1,023 participants · Phase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia